红日药业补缴税款3384万元,恒瑞医药1类新药获批临床,易明医药获1932万元政府补助,兄弟科技前三季度净利预增逾207%

谈医说药
Sep 16

奥翔药业:近日全资子公司浙江麒正药业有限公司收到国家药品监督管理局核准签发的甲磺酸伊马替尼片《药品注册证书》。甲磺酸伊马替尼片是全球首个抗肿瘤分子靶向药物,用于治疗慢性粒细胞白血病(CML)急变期、加速期或α-干扰素治疗失败后的慢性期患者、不能手术切除或发生转移的恶性胃肠道间质肿瘤(GIST)患者。步长制药:控股子公司上海合璞医疗科技有限公司拟对外投资共490万元,分别与济南恒德科技发展有限公司、...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10